Key Points:
- Despite available methods, CRC screening rates are low, with the immunological fecal occult blood test (FIT) showing a participation rate of only 36% in France, lower than the recommended 45%.
- Research is focusing on DNA tests that analyze cell-free DNA (cfDNA) from blood, which could potentially increase screening compliance by simplifying the process and detecting CRC earlier.
- The study evaluated cfDNA blood tests for CRC screening, finding a sensitivity of 83.1% for detecting CRC via colonoscopy.
- However, the sensitivity for detecting advanced polyps was low at 13.2%, indicating a limitation in preventing CRC by not catching these precancerous lesions effectively.